	US 11,946,084 B2
	Fusion protein comprising a Pab1 element and an eIF4G element and use of the fusion protein for improving protein synthesis
Min Guo, Shanghai (CN); Shuailong Liu, Shanghai (CN); and Xue Yu, Shanghai (CN)
Assigned to KANGMA-HEALTHCODE (SHANGHAI) BIOTECH CO., LTD, Shanghai (CN)
Appl. No. 16/633,524
Filed by KangMa-Healthcode (Shanghai) Biotech Co., Ltd, Shanghai (CN)
PCT Filed Dec. 13, 2017, PCT No. PCT/CN2017/115972 § 371(c)(1), (2) Date May 22, 2020, PCT Pub. No. WO2019/024379, PCT Pub. Date Feb. 7, 2019.
Claims priority of application No. 201710642517.4 (CN), filed on Jul. 31, 2017.
Prior Publication US 2021/0189449 A1, Jun. 24, 2021
Int. Cl. C12P 21/00 (2006.01); C07K 7/06 (2006.01); C12N 15/86 (2006.01)

CPC C12P 21/00 (2013.01) [C07K 7/06 (2013.01); C12N 15/86 (2013.01); C07K 2319/02 (2013.01)]

14 Claims

1. A fusion protein having a structure represented by the general Formula Ia or Formula Ib:

A-B-C (Ia)

C-B-A (Ib);

wherein,

A is a Pab1 protein;

B is a linker peptide or not present;

C is a eIF4G protein; and

each “-” is a peptide bond,

wherein the Pab1 protein and the eIF4G protein are both from Kluyveromyces lactis, or are both from Kluyveromyces marxianus, or are both from Kluyveromyces dobzhanskii, and

the Pab1 protein is a polyadenylate binding protein and has a sequence identity greater or equal to 95%, 97%, 98%, or 99% to the protein of SEQ ID NO: 1; and

the eIF4G protein is a translation initiation factor and has a sequence identity greater or equal to 97%, 98%, or 99% to the protein of SEQ ID NO: 2.